$27.180
+0.802 (+2.95%)收盘时
LYCA 同业对比
In the context of the broader market, LYCA competes directly with industry leaders such as IMCR and TYRA. With a market capitalization of $1.42B, it holds a significant position in the sector. When comparing efficiency, LYCA's gross margin of N/A stands against IMCR's 99.06% and TYRA's N/A. Such benchmarking helps identify whether Lycia Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.
Lycia Therapeutics, Inc. Common Stock 财务表现
The company has a forward P/E of 0 and a price-to-sales ratio of 310.1, indicating it may not be generating revenue relative to its market cap.
Financials
No data
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。